ClinicalTrials.gg
CompletedNCT06751121Updated Dec 8, 2025

Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori

A Phase 3 interventional study of DWP14012 40mg and DWC202301 30mg in Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients and Helicobacter Pylori Infected Subjects, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Feb 2024, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This study is designed to demonstrate the non-inferiority and verify the safety of DWP14012-based triple therapy compared to DWC202301-based triple therapy as the first-line eradication therapy in patients who are positive for Helicobacter pylori

02

Conditions studied

  • Helicobacter Pylori Infection
  • Helicobacter Pylori Infected Patients
  • Helicobacter Pylori Infected Subjects
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult males and females ≥19 and ≤75 years of age at the time of giving
  2. Those who have all positive test results for H. pylori (13C-urea breath test and CLO) at screening visit (Visit 1)

    • A positive 13C-UBT result
    • A positive CLO result
  3. Those who require treatment for H. pylori eradication as at least one of the following applies:

    • Those who have peptic ulcer (gastric ulcer or duodenal ulcer) based on an upper gastrointestinal (GI) endoscopy at screening visit (Visit 1)
    • Those who have chronic atrophic gastritis based on an upper GI endoscopy at screening visit (Visit 1)
    • Those with a history of endoscopic resection of early gastric cancer or gastric adenoma

Exclusion criteria

Exclusion Criteria:

  1. Those with significant upper GI bleeding
  2. Those with a history of a surgical procedure that might affect gastric acid secretion (upper GI resection or vagotomy), or who are scheduled to undergo such procedure during this study
  3. Those with Zollinger-Ellison syndrome or other gastric acid hypersecretion disorders
  4. Those with a history of treatment for H. pylori eradication
  5. Those with a history of any within recent 5 years prior to screening visit (Visit 1)

    • However, they can participate if 5 years have passed without recurrence after determined to achieve a complete remission (the complete removal of tumors through surgical procedures or the end of anticancer therapy)
    • Still, those with a history of malignancies in the digestive system, except early gastric cancer under the inclusion criteria, are excluded irrespective of a complete remission
  6. Those who have experienced acute coronary artery disease (unstable angina, myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention), peripheral arterial disease and cerebrovascular disease (, stroke) within 24 weeks prior to screening visit (Visit 1)
  7. Those with systemic bleeding disorders, coagulation disorders, or severe blood disorders that make them ineligible for participation in this study
  8. Those with acquired immunodeficiency syndrome (AIDS) or viral hepatitis (tested positive for HBs antigen or antibody) (However, subjects who are negative for HCV-RNA can participate.)
  9. Those who meet the following criteria according to the results of the hepatic or renal level test performed at screening visit (Visit 1)

    • At least one of , AST, ALP, γ-GTP and total > 2 times the
    • BUN > 2 times the upper limit of normal
    • (CrCl) ≤ 30 mL/min
  10. Patients with uncontrolled hypertension (systolic blood pressure of ≥ 160 mmHg or diastolic blood pressure of ≥ 100 mmHg at screening)
  11. Patients with uncontrolled diabetes ( > 9.0 % at screening)
  12. Patients with one or more of the following:

    • Heart failure ( Class III \~ IV)
    • History of or ventricular arrhythmias (including Torsades de pointes)
  13. Patients with hypokalemia (Potassium \< 3 mmol/L at screening)
  14. Patients with hypomagnesemia (Magnesium \< 1.2 mg/dL at screening)
  15. Those with clinically significant mental disorders
  16. Patients with central nervous system infection
  17. Patients with infectious mononucleosis
  18. Those with a history of drug or alcohol abuse within recent 1 year prior to screening visit (Visit 1)
  19. Those with a history of or allergy to the IP, amoxicillin, clarithromycin, drugs used for 13C-UBT, or premedications for an upper GI endoscopy, or their components
  20. Those with a history of hypersensitivity or allergy to proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs), benzimidazoles, penicillin antibiotics, or macrolide antibiotics
  21. Those who are taking, or need to take, at least one of the following:

    • Atazanavir, Rilpivirine, or drugs that contain any of them
    • Pimozide, Domperidone
    • Ergot alkaloid and its derivatives (Ergotamine, Dihydroergotamine, etc.)
    • Mizolastine
    • Ticagrelor
    • Colchicine
  22. Those who have a history of use of any PPIs, P-CABs or H2-receptor antagonists within recent 14 days prior to 13C-UBT of screening visit (Visit 1), or who need to take any of them during the study
  23. Those who have a history of use of bismuth or any antibiotics known to be effective at eradication of H. pylori within recent 28 days prior to 13C-UBT of screening visit (Visit 1), or who need to take any of them during the study
  24. For those using antibiotic resistance test results or samples prior to the screening visit (Visit 1), the subjects who have a history of antibiotic use from the time the results or samples were obtained (up to 90 days prior to the screening visit)
  25. Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
  26. Those to whom an upper GI endoscopy cannot be performed
  27. Pregnant or lactating women
  28. Those who do not agree to use a proper throughout the study duration

    • Proper contraception methods for the subject or his/her partner
    • Sterilization (vasectomy, etc.), or intrauterine devices (copper loop, intrauterine systems containing hormones)
    • Combined use of barrier methods with any one of non-oral hormonal contraceptives or spermicides
    • Combined use of a cervical cap or contraceptive diaphragm with male condoms
  29. Those who have participated in other studies, and have been treated with the IP or medical device at least once within 4 weeks prior to participating in this study
  30. Those deemed ineligible to participate in this study based on the investigator's other medical opinions
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    DWP14012 40 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg

    1 tablet of DWP14012 40 mg + 1 capsule of DWC202301 30 mg placebo + amoxicillin 1000 mg (2 capsules of 500 mg) + 1 tablet of clarithromycin 500 mg

    Drug: DWP14012 40mg · Drug: Amoxicillin 1000mg · Drug: Clarithromycin 500mg · Drug: DWC202301 30mg placebo

  • Active comparator
    DWC202301 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg

    1 tablet of DWP14012 40 mg placebo + 1 capsule of DWC202301 30 mg + amoxicillin 1000 mg (2 capsules of 500 mg) + 1 tablet of clarithromycin 500 mg

    Drug: DWC202301 30mg · Drug: Amoxicillin 1000mg · Drug: Clarithromycin 500mg · Drug: DWP14012 40mg placebo

Interventions

  • DWP14012 40 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).

  • DrugDWC202301 30mg

    DWC202301 30 mg, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).

  • Amoxicillin 1000 mg(2 capsules of 500mg), capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days).

  • Clarithromycin 500 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)

  • DrugDWC202301 30mg placebo

    DWC202301 30 mg placebo, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)

  • DrugDWP14012 40mg placebo

    DWP14012 40 mg placebo, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)

06

What researchers measure

Primary outcomes

  1. H. pylori eradication rate

    H. pylori eradication rate identified by 13C-UBT after at least 4 weeks (28 - 56 days) from the end of treatment

    Time frame: after at least 4 weeks (28 - 56 days) from the end of treatment

Secondary outcomes

  1. H. pylori eradication rate(for subjects who are resistant to clarithromycin)

    H. pylori eradication rate identified by 13C-UBT after at least 4 weeks (28 - 56 days) from the end of treatment (for subjects who are resistant to clarithromycin)

    Time frame: after at least 4 weeks (28 - 56 days) from the end of treatment

  2. H. pylori eradication rate(for subjects who are not resistant to clarithromycin or amoxicillin)

    H. pylori eradication rate identified by 13C-UBT after at least 4 weeks (28- 56 days) from the end of treatment (for subjects who are not resistant to clarithromycin or amoxicillin)

    Time frame: after at least 4 weeks (28- 56 days) from the end of treatment

07

Study locations

1 site
  • Asan Medical Center
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Apr 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
Dec 27, 2024
StartActual
Feb 6, 2024
Primary completionActual
Apr 24, 2025
CompletionActual
Apr 24, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06751121
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Feb 6, 2024
Primary completion
Apr 24, 2025
Completion
Apr 24, 2025
Last update
Dec 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion